The group's principal activities are to discover and develop proprietary drugs used in prevention of cardiac diseases. The group focuses on four projects designed to prevent or treat atrial and ventricular arrhythmia namely: RSD1235, RSD1122 and KV1.5 and Oxypurinol. On 8-Mar-2002, the group acquired Paralex, Inc.
Executive Information
Name
Title
Email
Robert Rieder
Chmn., CEO
N/A
Charles Fisher
Chief Medical Officer - Executive Vice Presidant, Clinical, Regulatery Affairs
